In short, yes. When the skin exhibits signs of irritation—such as erythema, pruritus, or a burning sensation—the stratum corneum is likely compromised. Continuing the use of potent active ingredients like retinoids, alpha-hydroxy acids (AHAs), or L-ascorbic acid can exacerbate this damage by further increasing transepidermal water loss (TEWL) and triggering an inflammatory cytokine cascade [1]. During this period, the skin’s primary biological focus is wound healing and barrier restoration, and the introduction of exogenous irritants interferes with this delicate homeostatic process.
Evidence suggests that maintaining a 'skinalysis' period of 72 hours to two weeks, where all sensitising actives are withdrawn, allows the lipid bilayer to reorganise. By stripping back to a physiological lipid-mimicking moisturiser (containing ceramides, cholesterol, and fatty acids), you facilitate the natural repair of the permeability barrier [2]. Failing to pause actives during irritation can lead to chronic low-grade inflammation, which paradoxically accelerates skin ageing—a process often termed 'inflammaging' [3].
The skin barrier consists of a 'bricks-and-mortar' structure where corneocytes are embedded in a lipid-rich extracellular matrix. Irritation signifies a disruption in this matrix, often caused by over-exfoliation or environmental stressors, leading to the activation of the innate immune system and the release of inflammatory mediators like Interleukin-1α [4]. Once this barrier is breached, active ingredients that were previously tolerated can penetrate deeper into the dermis, causing neurosensory irritation and further structural degradation.
From a biomedical perspective, the recovery phase requires the suppression of proteolytic enzymes that break down desmosomes and the promotion of filaggrin production. Clinical studies indicate that occlusive and humectant-rich formulations are essential during this phase to provide an artificial seal, reducing the metabolic load on the skin as it synthesises new lipids [2][5]. Only once the barrier is functionally intact—indicated by the absence of redness and stinging—should active ingredients be reintroduced systematically.
For those looking to support their skin during this recovery phase, our Surface Calm was formulated with essential ceramides and panthenol to provide a non-stripping, barrier-safe cleansing experience. To further assist with microbiome support and daily hydration while the skin remains sensitised, some of our customers have found that following with Balance Biome Crème helps to foster a more resilient and balanced complexion.
FAQ
Which specific active ingredients should I stop using first?
You should immediately cease the use of all direct acids (AHAs, BHAs), retinoids (Retinol, Tretinoin), and high-strength Vitamin C (L-ascorbic acid). These ingredients are designed to increase cell turnover or have a low pH, both of which can intensify irritation in a compromised barrier [1]. Even physical exfoliants and fragranced products should be avoided to minimise the risk of contact dermatitis [6].
Are there any 'actives' that are safe to keep using?
Yes, certain ingredients often classified as 'actives' are actually beneficial for repair. Niacinamide (Vitamin B3) at concentrations below 5% can stimulate ceramide synthesis and strengthen the barrier [7]. Additionally, panthenol (Pro-vitamin B5), allantoin, and centella asiatica are evidence-based soothing agents that help downregulate inflammation and support re-epithelialisation without causing further irritation [5].
How do I know when it is safe to restart my routine?
Reintroduction should only occur when the skin has returned to its clinical baseline for at least three consecutive days. This means no visible redness, no texture changes, and a 'zero-sting' response to a basic moisturiser [2]. When restarting, it is vital to reintroduce actives one at a time, starting with lower frequencies (e.g., twice weekly) to monitor the skin’s tolerance levels [6].
References:
[1] Del Rosso JQ, et al. Journal of Clinical and Aesthetic Dermatology. 2016;9(9):S2-S8. doi:10.12788/j.sder.2016.035
[2] Pappas A. Dermato-Endocrinology. 2009;1(2):72-76. doi:10.4161/derm.1.2.7811
[3] Zhuang Y, et al. International Journal of Molecular Sciences. 2022;23(21):13210. doi:10.3390/ijms232113210
[4] Proksch E, et al. Experimental Dermatology. 2008;17(12):1063-1072. doi:10.1111/j.1600-0625.2008.00774.x
[5] Draelos ZD. Journal of Cosmetic Dermatology. 2018;17(2):136-142. doi:10.1111/jocd.12457
[6] Levin J, et al. Journal of Clinical and Aesthetic Dermatology. 2010;3(2):22-41.
[7] Gehring W. American Journal of Clinical Dermatology. 2004;5(2):129-137. doi:10.2165/00128071-200405020-00008
